Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 79

Sort by

Sort Order Select

Journal Articles

BCMA-Directed Low Dose Alpha-Emitter Therapy Eliminates Minimal Residual Disease in a Multiple Myeloma Mouse Xenograft Model

Melissa L Comstock, Shyril O'Steen, Yukang Lin, Donald Hamlin, D Scott Wilbur, Johnnie J. Orozco, Rainer F. Storb, Roland B. Walter, Pinar Ataca Atilla, Brian G Till, Geoffrey R Hill, Brenda M. Sandmaier, Damian J Green

Blood (2023) 142 (Supplement 1): 53.

https://doi.org/10.1182/blood-2023-188055

Published: 2023

Journal Articles

Pre-Transplant Monocytic Myeloid-Derived Suppressor Cell Frequency Has No Prognostic Role for Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in Remission

Colin Godwin, Jonathan R. Fromm, MD PhD, Brenda M. Sandmaier, MD, Marco Mielcarek, MD, Brent Wood, MD PhD, Frederick R. Appelbaum, MD, Rainer F. Storb, MD, Roland B. Walter, MD PhD MS

Blood (2018) 132 (Supplement 1): 5255.

https://doi.org/10.1182/blood-2018-99-117745

Published: 2018

Journal Articles

Safety and Efficacy of Yttrium-90-Labeled Anti-CD45 Antibody ( 90 Y-DOTA-BC8) Followed By a Standard Reduced-Intensity Hematopoietic Stem Cell Transplant (HCT) Regimen for Patients with Refractory/Relapsed Leukemia or High-Risk Myelodysplastic Syndrome (MDS)

Phuong T. Vo, MD, Ted Gooley, PhD, Joseph G. Rajendran, MD, Darrell R. Fisher, PhD, Johnnie J. Orozco, MD PhD, Damian J. Green, MD, Ajay K. Gopal, MD, Robyn Haaf, BS, Margaret E. Nartea, BS, Rainer F. Storb, MD, Frederick R. Appelbaum, MD, Oliver W. Press, MD PhD, John M. Pagel, MD PhD, Brenda M. Sandmaier, MD

Blood (2018) 132 (Supplement 1): 1018.

https://doi.org/10.1182/blood-2018-99-111915

Published: 2018

Journal Articles

Anti-CD45 Radioimmunotherapy Followed By Haploidentical Allogeneic Hematopoietic Cell Transplantation for Advanced Acute Leukemia or High-Risk MDS

Blood (2017) 130 (Supplement 1): 2048.

https://doi.org/10.1182/blood.V130.Suppl_1.2048.2048

Published: 2017

Journal Articles

Long-Term Follow up of 90 y-Ibritumomab Tiuxetan, Fluadarabine and TBI Based Non-Myeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B-Cell Lymphoma

Camille E. Puronen, MD, Ryan D. Cassaday, MD, Philip A. Stevenson, MS, Brenda M. Sandmaier, MD, Mary E. Flowers, MD, Damian J. Green, MD, David G. Maloney, MD PhD, Rainer F. Storb, MD, Oliver W. Press, MD PhD, Ajay K. Gopal, MD

Blood (2017) 130 (Supplement 1): 4559.

https://doi.org/10.1182/blood.V130.Suppl_1.4559.4559

Published: 2017

Journal Articles

Total Body Irradiation (TBI) Dose Escalation Decreases Risk of Progression and Graft Rejection after Hematopoietic Cell Transplantation with Nonmyeloablative Conditioning for Myelodysplastic Syndrome (MDS) or Myeloproliferative Neoplasms (MPN)

Federico Monaco, MD, Bart L. Scott, MD, Thomas Chauncey, MD PhD, Finn Petersen, MD, Barry E. Storer, PhD, Frederic Baron, Mary E. Flowers, MD, H. Joachim Deeg, MD, Rainer F. Storb, MD, David G. Maloney, MD PhD, Brenda M. Sandmaier, MD

Blood (2017) 130 (Supplement 1): 908.

https://doi.org/10.1182/blood.V130.Suppl_1.908.908

Published: 2017

Journal Articles

Decoding the RNA Editome of Normal Versus Malignant Progenitor Cell Aging Short Title: RNA Editing in Normal Aging and MDS/AML Stem Cells

Leslie A Crews, PhD, Qingfei Jiang, PhD, Larisa Balaian, PhD, Heather Leu, BS, Nathan Delos Santos, Angela C Court, Anil Sadarangani, PhD, Sheldon Morris, MD, Rainer F. Storb, MD, Anna Kulidjian, MD, Edward D. Ball, MD, Catriona Jamieson, MD PhD

Blood (2016) 128 (22): 1519.

https://doi.org/10.1182/blood.V128.22.1519.1519

Published: 2016

Journal Articles

Prophylactic Natural Killer Cell Immunotherapy Following HLA-Haploidentical Hematopoietic Cell Transplantation Prevents Relapse and Improves Survival in Patients with High-Risk Hematological Malignancies

Monica Thakar, MD, Parameswaran Hari, MD MRCP, MS, David G. Maloney, MD PhD, Carolyn A. Keever-Taylor, PhD, Lori Jones, PhD, Shelly Heimfeld, PhD, Rainer F. Storb, MD, Brenda M. Sandmaier, MD

Blood (2016) 128 (22): 1161.

https://doi.org/10.1182/blood.V128.22.1161.1161

Published: 2016

Journal Articles

Reversal of Low Donor Chimerism Following Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion

Merav Bar, MD, Mary Flowers, MD, Barry E. Storer, PhD, Thomas R. Chauncey, MD PhD, Michael A Pulsipher, MD, Monica S Thakar, MD, Wolfgang Bethge, MD, Rainer F. Storb, MD, David G Maloney, Brenda M. Sandmaier, MD

Blood (2016) 128 (22): 2215.

https://doi.org/10.1182/blood.V128.22.2215.2215

Published: 2016

Journal Articles

Addition of Astatine-211-Labeled Anti-CD45 Antibody to Total Body Irradiation (TBI) As Conditioning for DLA-Identical Marrow Transplantation: A Novel Strategy to Overcome Graft Rejection in a Canine Presensitization Model

Huiying Qiu, MD, Erlinda B Santos, Rainer F. Storb, MD, Donald K Hamlin, D Scott Wilbur, PhD, Brenda M Sandmaier, MD

Blood (2016) 128 (22): 2152.

https://doi.org/10.1182/blood.V128.22.2152.2152

Published: 2016

Journal Articles

Sirolimus Combined with Mycophenolate Mofetil (MMF) and Cyclosporine (CSP) Significantly Improves Prevention of Acute Graft-Versus-Host-Disease (GVHD) after Unrelated Hematopoietic Cell Transplantation (HCT): Results from a Phase III Randomized Multi-Center Trial

Brenda M Sandmaier, MD, David G Maloney, MD PhD, Barry E. Storer, PhD, Gitte Olesen, MD, Michael B. Maris, MD, Jonathan A Gutman, MD, Soren Lykke Petersen, MD DMSC, Amelia Langston, MD, Thomas Chauncey, Wolfgang Bethge, MD, Michael A Pulsipher, MD, Brian Thomas Kornblit, MD PhD, Ann E Woolfrey, MD, Marco Mielcarek, MD, Paul J. Martin, MD, Mary E.D. Flowers, MD, Rainer F. Storb, MD

Blood (2016) 128 (22): 506.

https://doi.org/10.1182/blood.V128.22.506.506

Published: 2016

Journal Articles

It Is Easix to Predict Non-Relapse Mortality (NRM) of Allogeneic Stem Cell Transplantation (alloSCT)

Thomas Luft, MD PhD, Axel Benner, Sonata Jodele, MD, Christopher E. Dandoy, MD, Rainer F. Storb, MD, Ted A. Gooley, PhD, Brenda M. Sandmaier, MD, Aleksandar Radujkovic, MD, Anthony D. Ho, MD, Peter Dreger, MD, Olaf Penack, MD

Blood (2016) 128 (22): 519.

https://doi.org/10.1182/blood.V128.22.519.519

Published: 2016

Journal Articles

RNA Splicing Modulation Impairs Acute Myeloid Leukemia Stem Cell Maintenance

Leslie A Crews, PhD, Larissa Balaian, PhD, Heather Leu, BS, Nathaniel Delos Santos, Angela C Court, Anil Sadarangani, PhD, Maria A. Zipeto, PhD, James J La Clair, Reymundo Villa, Sheldon Morris, MD, Rainer F. Storb, MD, Anna Kulidjian, MD, Edward D. Ball, MD, Michael D Burkart, PhD, Catriona Jamieson, MD PhD

Blood (2015) 126 (23): 567.

https://doi.org/10.1182/blood.V126.23.567.567

Published: 2015

Journal Articles

Pre-Transplant Ferritin, Albumin and Platelet Count Add Prognostic Information to Comorbidities for Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes: A Multi-Center Discovery-Validation Study

Jennifer E. Vaughn, MD MSPH, Barry E. Storer, PhD, Philippe Armand, MD PhD, Roberto Raimondi, MD, Christopher J Gibson, MD, Alessandro Rambaldi, MD, Fabio Ciceri, MD, Rosi Oneto, MD, Benedetto Bruno, MD PhD, Paul J. Martin, MD, Brenda M. Sandmaier, MD, Rainer F. Storb, MD, Mohamed L. Sorror, MD MSc

Blood (2014) 124 (21): 421.

https://doi.org/10.1182/blood.V124.21.421.421

Published: 2014

Journal Articles

Role of Comorbidities in Prognostic Evaluation of Outcomes Following Allogeneic Hematopoietic Cell Transplantation (HCT) from HLA-Mismatched (MM) and Umbilical Cord Blood (UCB) Donor Grafts

Mahmoud Elsawy, MD MSc, Barry E. Storer, PhD, Brenda M. Sandmaier, MD, Colleen Delaney, MD MSC, Frederick R. Appelbaum, MD, Ann E Woolfrey, MD, David G Maloney, MDPhD, Rainer F. Storb, MD, Mohamed L. Sorror, MD MSc

Blood (2014) 124 (21): 2583.

https://doi.org/10.1182/blood.V124.21.2583.2583

Published: 2014

Journal Articles

Posttransplant Cyclophosphamide for Prevention of Graft-Versus-Host Disease after HLA-Matched Related and Unrelated Donor Peripheral Blood Stem Cell Transplantation

Marco Mielcarek, MD, Terrence Furlong, Paul V. O'Donnell, MD PhD, Barry E. Storer, PhD, Rainer F. Storb, MD, Paul A. Carpenter, MD, Paul J. Martin, MD

Blood (2014) 124 (21): 1161.

https://doi.org/10.1182/blood.V124.21.1161.1161

Published: 2014

Journal Articles

Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality

Mohamed L. Sorror, Paul J. Martin, Rainer F. Storb, Smita Bhatia, Richard T. Maziarz, Michael A. Pulsipher, Michael B. Maris, Christopher Davis, H. Joachim Deeg, Stephanie J. Lee, David G. Maloney, Brenda M. Sandmaier, Frederick R. Appelbaum, Theodore A. Gooley

Blood (2014) 124 (2): 287–295.

https://doi.org/10.1182/blood-2014-01-550566

Published: 2014

Journal Articles

Late effects among pediatric patients followed for nearly 4 decades after transplantation for severe aplastic anemia

Jean E. Sanders, Ann E. Woolfrey, Paul A. Carpenter, Barry E. Storer, Paul A. Hoffmeister, H. Joachim Deeg, Mary E. D. Flowers, Rainer F. Storb

Blood (2011) 118 (5): 1421–1428.

https://doi.org/10.1182/blood-2011-02-334953

Published: 2011

Journal Articles

90 Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma

Ajay K. Gopal, Katherine A. Guthrie, Joseph Rajendran, John M. Pagel, George Oliveira, David G. Maloney, Manuela C. Matesan, Rainer F. Storb, Oliver W. Press

Blood (2011) 118 (4): 1132–1139.

https://doi.org/10.1182/blood-2010-12-324392

Published: 2011

Journal Articles

Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation

Yoshihiro Inamoto, Mary E. D. Flowers, Stephanie J. Lee, Paul A. Carpenter, Edus H. Warren, H. Joachim Deeg, Rainer F. Storb, Frederick R. Appelbaum, Barry E. Storer, Paul J. Martin

Blood (2011) 118 (2): 456–463.

https://doi.org/10.1182/blood-2011-01-330217

Published: 2011

Includes: Supplemental data

NARROW

BCMA-Directed Low Dose Alpha-Emitter Therapy Eliminates Minimal Residual Disease in a Multiple Myeloma Mouse Xenograft Model

Pre-Transplant Monocytic Myeloid-Derived Suppressor Cell Frequency Has No Prognostic Role for Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in Remission

Safety and Efficacy of Yttrium-90-Labeled Anti-CD45 Antibody ( 90 Y-DOTA-BC8) Followed By a Standard Reduced-Intensity Hematopoietic Stem Cell Transplant (HCT) Regimen for Patients with Refractory/Relapsed Leukemia or High-Risk Myelodysplastic Syndrome (MDS)

Anti-CD45 Radioimmunotherapy Followed By Haploidentical Allogeneic Hematopoietic Cell Transplantation for Advanced Acute Leukemia or High-Risk MDS

Long-Term Follow up of 90 y-Ibritumomab Tiuxetan, Fluadarabine and TBI Based Non-Myeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B-Cell Lymphoma

Total Body Irradiation (TBI) Dose Escalation Decreases Risk of Progression and Graft Rejection after Hematopoietic Cell Transplantation with Nonmyeloablative Conditioning for Myelodysplastic Syndrome (MDS) or Myeloproliferative Neoplasms (MPN)

Decoding the RNA Editome of Normal Versus Malignant Progenitor Cell Aging Short Title: RNA Editing in Normal Aging and MDS/AML Stem Cells

Prophylactic Natural Killer Cell Immunotherapy Following HLA-Haploidentical Hematopoietic Cell Transplantation Prevents Relapse and Improves Survival in Patients with High-Risk Hematological Malignancies

Reversal of Low Donor Chimerism Following Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion

Addition of Astatine-211-Labeled Anti-CD45 Antibody to Total Body Irradiation (TBI) As Conditioning for DLA-Identical Marrow Transplantation: A Novel Strategy to Overcome Graft Rejection in a Canine Presensitization Model

Sirolimus Combined with Mycophenolate Mofetil (MMF) and Cyclosporine (CSP) Significantly Improves Prevention of Acute Graft-Versus-Host-Disease (GVHD) after Unrelated Hematopoietic Cell Transplantation (HCT): Results from a Phase III Randomized Multi-Center Trial

It Is Easix to Predict Non-Relapse Mortality (NRM) of Allogeneic Stem Cell Transplantation (alloSCT)

RNA Splicing Modulation Impairs Acute Myeloid Leukemia Stem Cell Maintenance

Pre-Transplant Ferritin, Albumin and Platelet Count Add Prognostic Information to Comorbidities for Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes: A Multi-Center Discovery-Validation Study

Role of Comorbidities in Prognostic Evaluation of Outcomes Following Allogeneic Hematopoietic Cell Transplantation (HCT) from HLA-Mismatched (MM) and Umbilical Cord Blood (UCB) Donor Grafts

Posttransplant Cyclophosphamide for Prevention of Graft-Versus-Host Disease after HLA-Matched Related and Unrelated Donor Peripheral Blood Stem Cell Transplantation

Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality

Late effects among pediatric patients followed for nearly 4 decades after transplantation for severe aplastic anemia

90 Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma

Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only